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The clinical relevance of the bidirectional cross-talk between heart and kidney is increasingly recognized. However, the optimal
approach to the management of kidney dysfunction in heart failure remains unclear. The purpose of this article is to outline the
most plausible pathophysiologic theories that attempt to explain the renal impairment in acute and chronic heart failure, and to
review the current treatment strategies for these situations.
1.Introduction
Heart and kidney are inextricably linked to maintain home-
ostasis. Communication between these two organs occurs
at multiple levels including the sympathetic nervous system
(SNS), the renin-angiotensin-aldosterone system (RAAS),
the antidiuretic hormone, endothelin, or the natriuretic
peptides. The dysfunction of one of them contributes to the
dysfunction of the other; renal dysfunction impairs cardiac
performance, which again leads to further impairment of
renal function. The term “cardiorenal syndrome” (CRS)
was coined to deﬁne this situation, but a consensus of the
diagnostic criteria has not been reached yet. Initially, it was
characterized as a state in which therapy to relieve congestive
heart failure (HF) symptoms was limited by further wors-
ening renal function [1]. Although this deﬁnition does not
accurately describe the complexity of its nature, it portrays
a common situation in daily clinical practise. A broader
deﬁnition of the CRS was developed by the Acute Dialysis
Quality Initiative [2].
The CRS was classiﬁed into ﬁve categories, according
to the underlying etiologies and the nature of concomitant
cardiac and renal dysfunction (Table 1). Heart failure seems
to be the primary failing organ in two of the ﬁve described
features. CRS type 1 occurs when acute decompensated
heart failure (ADHF) leads to acute kidney injury. CRS
type 2 refers to the development of a progressive worsening
of renal function (WRF) in the setting of chronic heart
failure (CHF). Both, acute and progressive development
of renal dysfunction in patients with heart failure, have
been associated with independently worse outcomes com-
pared with preserved renal function [3–13]. Therefore,
a precise understanding of the pathophysiology of this
syndromeisneededtoprovidetherationaleformanagement
strategies.
2.Pathophysiology
The pathophysiology of the cardiorenal syndrome remains
unclear but can be attributed to three main factors: low-
cardiac output, elevation of both intra-abdominal and cen-
tralvenouspressures,andneurohormonalandinﬂammatory
activation [14, 15]. The terms “backward failure” and
“forward failure” have been historically used to classify HF
syndrome. Although not commonly used nowadays, this
classiﬁcation allows an intuitive approach to understand the
underlying mechanisms of these forms of CRS. Forward
failure implies arterial underﬁlling, which leads to a low-
ﬂow state. This appears to be one of the cornerstones in the
development of CRS, but not the only one. Improvement
in cardiac index did not always result in improved renal
function. Multiple studies support this conclusion: The
EvaluationStudyofCongestiveHeartFailureandPulmonary
Catheterization Eﬀectiveness (ESCAPE) trial associated2 International Journal of Nephrology
baseline kidney dysfunction (estimated glomerular ﬁltration
rate,-GFR-,<60mL/min)atadmissionandatdischargewith
anincreasedriskofdeathandrehospitalization[16].Patients
randomized to the group, in which therapy was guided by
clinical assessment and a pulmonary artery catheter (PAC),
presented signiﬁcantly less deterioration of kidney function,
compared with a therapy based on clinical assessment alone,
but this did not imply an improvement in clinical outcomes
in patients with baseline CKD. Incidence of WRF during
hospitalization (serum creatinine > 0.3mg/dL) was similar
in both arms, and was not associated to increased outcomes
of death or rehospitalization. Among hemodynamic param-
eters measured in the PAC arm, only right atrial pressure
correlated weakly with baseline serum creatinine (r = 0.165,
P = .03). Similar results were obtained by Mullens et al. [17].
They studied 145 patients admitted with ADHF and treated
with intensive medical therapy guided by pulmonary artery
catheter. Patients who developed WRF did not have a lower
cardiac index on admission or at discharge when compared
with those without WRF. The mean baseline cardiac index
was signiﬁcantly greater in subjects who developed WRF
versus those who did not (2.00 ± 0.8l/min/m2 versus 1.8
± 0.4l/min/m2, P = .008). At follow-up, the mean cardiac
indexandthecentralvenouspressureremainedsuperior(2.7
± 0.7l/min/m2 versus 2.4 ± 0.5l/min/m2, P = .01 and 11 ±
8mmHgversus8±5mmHg,P = .04,resp.)insubjectswho
developed WRF.
These ﬁndings support the hypothesis that there must
be another mechanism that contributes to renal impairment
in heart failure. Rising renal venous pressure limits urine
formation and renal ﬂow. Several mechanisms have been
proposed to explain this situation. Backward failure implies
that systemic venous congestion also aﬀects renal venous
pressure and function (congestive kidney failure), by direct
hypoxic damage or through RAAS/SNS stimulation way.
A substudy of the Studies of Left Ventricular Dysfunction
(SOLVD) established the prognostic implication of jugu-
lar venous pressure on patients with CHF [18]. Patients
with increased venous pressure had a signiﬁcantly higher
serum creatinine level (115 ± 27 versus 106 ± 27μmol/L).
Interestingly, Mullens et al. also described that patients who
developed WRF had greater central venous pressure on
admission (18 ± 7mmHgversus12± 6mmHg,P = .001)
and after intensive medical therapy (11 ± 8mmHgversus
8 ± 5mmHg, P = .04) [17]. The development of WRF
occurred less frequently in patients who achieved a central
venous pressure <8mmHg. Damman et al. evaluated right
atrial pressure and cardiac index by right heart catheteri-
sation, in 51 patients with cardiac dysfunction, secondary
to pulmonary hypertension [19]. In a multivariate analysis,
low renal blood ﬂow and high right atrial pressure were
independently associated with lower GFR.
Intra-abdominal pressure has been considered an alter-
native pathway to explain how decompensated HF may
lead to WRF. Increased abdominal pressure may lead
to renal impairment by a “compressing eﬀect” in renal
parenchyma. Hence, elevated intra-abdominal pressure
(deﬁnedas>8mmHg) hasbeen associatedwithsigniﬁcantly
lower GFR compared with those with normal IAP in patients
Table 1: Cardiorenal syndrome: classiﬁcation.
CRS type 1 Development of acute kidney injury in the setting
of a sudden deterioration of heart function
CRS type 2 Progressive renal dysfunction in the setting of
chronic cardiac dysfunction
CRS type 3 Abrupt and primary worsening of renal function
leads to acute heart failure
CRS type 4 Primary chronic kidney disease contributes to the
progressive development of chronic heart failure
CRS type 5 Combined cardiac and renal dysfunction caused
by a systemic illness
Table 2: Summary of recommendations for clinical practice.
(i) Search for reversible causes: concomitant medications,
hypovolemia, hypotension, and urinary tract obstruction
(ii) Loop diuretics are useful to alleviate congestive symptoms but
should be used with caution: check renal function and serum
electrolytes closely
(iii) ACEI, ARA II, and aldosterone antagonists should be add, in
case of heart failure and systolic dysfunction: check renal function
and serum electrolytes closely
(iv) Ultraﬁltration may be considered refractory to diuretics in
symptomatic patients
(v) Correcting anemia should be considered in cardiorenal
syndrome type 2
with advanced decompensated HF (mean LVEF 19%) [20].
These authors also studied the eﬀect of mechanical ﬂuid
removal to reduce IAP in patients with ADHF, showing a
strong correlation (r = 0.77, P<. 001) was observed between
improved renal function in patients reduction in IAP and
with baseline elevated IAP [21].
In any case, hemodynamic changes do not fully explain
the whole cardiorenal connection. Interventions focused on
the interactions of the networks which link both systems
(RAAS, imbalance between reactive oxygen species and
nitric oxide, sympathetic nervous system and inﬂammation
processes) might help to control the progression of the CRS
[22].
3. Management of Worsening Renal
FunctionintheSettingofAcute
DecompensatedHeartFailure
Despite its common pathophysiology, each CRS’s type
embraces a broad spectrum of clinical features. Therefore,
therapies should be adapted to each single patient’s own
situation (Table 2).
Loop diuretics are ﬁrst-line agents to alleviate congestive
symptoms [23]. Although their use is widespread, there is
little evidence of their inﬂuence in managing CRS. Their
use may be associated with electrolyte abnormalities, further
neurohormonal activation and worsening renal function. In
addition,theymayincreasetherisktodevelopadverseeﬀects
of concomitant medications, such as angiotensin converting
enzyme inhibitors (ACEI), angiotensin II receptor blockersInternational Journal of Nephrology 3
(ARB), or spironolactone. Hence, the ﬁrst problem to deal
with is to strike a balance between removing volume to
relieve congestion without stimulating adverse eﬀects.
There is lack of evidence in the literature about this
topic, not only in AHF, but also in CKD patients, as
they are systematically excluded from randomized trials.
High-dose administration of intravenous loop diuretics has
been associated with worse outcomes in HF patients [24,
25]. Results of the Dose Optimization Strategy Evaluation
(DOSE) trial, recently presented at the American College of
Cardiology (ACC) 2010 Scientiﬁc Sessions, may highlight
this matter [26]. It included acute heart-failure patients with
a prior diagnosis of chronic heart failure (CHF) and daily
outpatient use of oral loop diuretics (80mg to 240mg) for
at least one month. Patients with serum creatinine >3mg/dL
were excluded. Patients were randomized to either high dose
(2.5 × their daily chronic oral furosemide dose given iv) or
low dose (their daily chronic oral furosemide dose given iv)
and were also randomized to dosing via intravenous bolus
or continuous infusion. Median baseline creatinine was
1.5mg/dL. The primary endpoints were symptom resolution
and change in serum creatinine from admission to 72 hours.
There were no signiﬁcant diﬀerences among the diﬀerent
dosing strategies forany of the twoendpoints. The high-dose
strategy showed greater symptom improvement, (P = .06),
but was also associated with mild increases in creatinine
levels, deﬁned as a > 0.3mg/dL rise in creatinine. There were
no diﬀerences among groups for death or rehospitalization
outcomes. Results of this trial suggest that, apparently, an
overaggressive use of loop diuretic is as safe as a conservative
treatment. If the response to loop diuretics is inadequate, a
thiazide should be added in a dose determined according
to the patient’s renal function. A synergistic response can
result in profound diuresis. These patients should, therefore,
be followed closely to prevent volume, magnesium, and
potassium depletion. Again, this empirical management,
which results to be eﬀective in daily practise, has not been
tested.
Vasodilators, such as intravenous nitroglycerin, are rec-
ommended at an early stage for AHF patients without
hypotension or serious obstructive valvular disease [23]. The
reduction in venous pressure may improve transrenal blood
ﬂow while protecting renal function, but doses that decrease
blood pressure may cause a decline in renal perfusion
and further activation of the RAAS. Although it has been
published that isosorbide dinitrate should have a beneﬁcial
eﬀect in patients with AHF [27], no randomized controlled
studies have been carried out to evaluate its role neither
in cardiorenal syndrome nor even in AHF. Nesiritide is a
recombinant analogue of human brain natriuretic peptide
for exogenous administration. The ASCEND trial (A Study
testing the Eﬀectiveness of Nesiritide in Patients with Acute
Decompensated Heart Failure) enrolled 7,141 patients with
severe HF, to determine whether nesiritide was superior to
placebo in reducing the HF related hospitalization rate or
all cause mortality at 30-days and improvement in dyspnea
at six or 24 hours. Patients were randomly assigned to
continuous intravenous nesiritide or placebo plus standard
treatment for 30 days. Compared with placebo, nesiritide
was not associated with a reduction in 30 day death or
HF rehospitalization (10.1% versus 9.4%; P = .31). Data
fromASCEND-HFshowednoassociationbetweennesiritide
and reduced renal function [28]. Vasopressin antagonists
selectively inhibit the V2 receptor of renal distal tubules and
collecting duct, increasing aquaresis and serum sodium in
those who are hyponatremic. Safety and eﬃcacy of these
agents have been tested in several trials in patients with
AHF during the acute phase. Although they have not proven
long-term beneﬁt on clinical outcomes, they could have a
favorable eﬀect on renal hemodynamics [29].
Adenosine A1 receptor antagonists improve renal blood
ﬂow and increase sodium excretion, by enhancing natriure-
sis, with preserving GFR, in combination with furosemide.
An ongoing trial (A Study of the Selective A1 Adenosine
Receptor Antagonist KW-3902 for Patients Hospitalized
With Acute HF and Volume Overload to Assess Treatment
Eﬀect on Congestion and Renal Function, PROTECT-2
study) is evaluating its application in ADHF patients.
Ultraﬁltration helps to remove the volume overload in
symptomatic patients refractory to diuretics. The Ultraﬁl-
tration versus Intravenous Diuretics for Patients Hospital-
ized for Acute Decompensated Congestive Heart Failure
(UNLOAD) trial demonstrated a greater weight loss in
ultraﬁltration group, as well as lower rehospitalization rates
and emergency department visits, compared to a diuretic-
based strategy [30].
Inotropic agents should be considered in patients with
low-output states in the presence of signs of hypoperfusion
or congestion despite the use of vasodilators and/or diuretics
[23]. Dobutamine has been associated to an increase in
renal blood ﬂow, proportional to the increase in cardiac
index. Low-dose dopamine has also been associated with
a theoretical eﬀect on renal blood ﬂow. Although it has
been proposed that an improvement in cardiac output
might lead to preserving renal function, this widespread
empirical therapy has not been tested in randomized trials.
Only milrinone and levosimendan have been evaluated in
this situation, and none of them have demonstrated an
improvement in renal function [15, 31].
4. Management of Renal Dysfunctionin
ChronicHeart Failure
Mechanisms which lead to a progressive renal impairment
in patients with CHF are still unclear. Several factors
may contribute to this situation, including hemodynamic
changes, diuretic’s side eﬀects, or a microvascular damage
secondary to a concomitant illness (such as hypertension or
diabetes).
Although many pharmacological and no pharmaco-
logical therapies have proven to be an advantage on sur-
vival in HF, their prescription is often limited by the
fear to develop complications attributable to WRF. The
results of the Registry to Improve the Use of Evidence-
Based Heart Failure Therapies in the Outpatient Setting
(IMPROVE HF) have been recently published [32]. The
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to AHA/ACC guidelines recommendations in the man-
agement of chro-nic heart failure (ACEIs/ARB, β-blockers,
aldoste-rone antagonists, cardiac resynchronization ther-
apy, implantable cardioverter deﬁbrillator, anticoagulation
if atrial ﬁbrillation/ﬂutter, and patient education) and to
determine the inﬂuence of renal dysfunction in applying
these therapies. It included 13,164 nonhospitalized patients
with severe systolic dysfunction (LVEF < 35%). Patients
were classiﬁed into four groups, according to their CKD
stage. Mean LVEF was around 25% in all groups. About
52% of the patients had a GFR <60mL/min/1.73m2.
The use of ACEI/ARB (87.4% in patients with GFR
>90mL/min/1.73m2 versus 57.9% in patients with GFR
<29mL/min/1.73m2, P<. 001), β-blockers (90.4% in
patients with GFR >90mL/min/1.73m2 versus 86.2% in
patients with GFR <29mL/min/1.73m2), and aldosterone
antagonists was signiﬁcantly lower in patients with a higher
stage of CKD. Multivariate analysis showed that the severity
of CKD was an independent predictor of adherence to
ACEI/ARB (HR 0.94; CI 95% 0.88–0.99; P = .018), but not
in the other recommended interventions.
Treatment with ACEI improves ventricular function (as
evidenced by an increased ejection fraction and decreased
ventricular size) and patient well-being, reduces hospital
admission for worsening HF, and increases survival. This
therapy should be used in all patients with symptomatic
HF and a LVEF < 40% [23]. As it is common to observe
a signiﬁcant increase in the serum creatinine concentration
(>0.3mg/dL) within the initiation of treatment with ACEI,
renal function should be closely monitored. ESC Guidelines
of management of HF accept a 50% increase in creatinine
serum level from baseline or an absolute concentration of
3mg/dL, whichever is lower. If creatinine rises between 3–
3.5mg/dL, ESC guidelines recommend to halve dose of
ACEI.TreatmentwithACEImustbeinterruptedifcreatinine
serum concentration rises above 3.5 mg/dL. ARB may be
considered as an alternative in patients who do not tolerate
ACEI. The inﬂuence on cardiorenal protection of RAAS
dual blockade, when an ARB is used in conjunction with
an ACEI, has also been analyzed in several trials. Among
patients with HF, combination therapy was associated with
further impairment in kidney function [33]. An aldosterone
antagonist should be added to treatment in symptomatic
patients with HF and an LVEF < 35% [23] .S i m i l a rt oA C E I ,
renal function should be closely monitored. If creatinine
rises above 2.5mg/dL (or potassium > 5.5 mmol/L), ESC
guidelines suggest to halve the spironolactone or eplerenone
doses. When serum creatinine is >3mg/dL (or potassium >
6mmol/L), treatment with aldosterone antagonists must be
discontinued.
The Canadian Cardiovascular Society includes among its
recommendations some options of management for these
patients. Thus, renal function must be checked daily in
patients with heart failure and increasing serum creatinine
more than 30% from baseline, and ACEI, ARB, and aldos-
terone dose should be reduced until renal function stabilizes.
In oliguric HF patients treatment with diuretics, ACEI, ARB,
or aldosterone should be reviewed daily. Routine use of
ACE inhibitors, ARBs or spironolactone in the setting of
severerenaldysfunction(serumcreatininelevelsgreaterthan
250μmol/L or an increase of more than 50% from baseline)
is not routinely recommended [34].
Despite these recommendations, it is important to
emphasize that serum creatinine concentration is not an
accurate measure of GFR. Creatinine serum levels vary
according to gender, person’s size, and muscle mass, and this
must be taken into account. The most common formula
for calculating the GFR has not been validated in acute
renal failure, but there is on increasing interest in new renal
biomarkers for the diagnosis and classiﬁcation of CRS, such
ascystatinCortheneutrophilgelatinase-associatedlipocalin
[35].
Anemia is a frequent and multifactorial ﬁnding in both
CKD and CHF. Its prevalence is similar among patients with
preserved and depressed LVEF. Neither ACC/AHA nor ESC
guidelines establish the correction of anemia as a systematic
target in patients with HF, although it has been associated
withpoorclinicaloutcomes.Eventhoughthereisactuallyno
deﬁnitive evidence to the optimum approach for the man-
agement of anemia in patients with CHF which develop a
progressiverenaldysfunction(cardiorenalsyndrometype2),
a pragmatical strategy for anemia correction, based on CKD
guidelines and HF trials, has been proposed [36]. Because
of the adverse cardiovascular eﬀects of higher hematocrit
in CKD trials, authors suggest a target hemoglobin of 10–
12g/dL at clinical practise. If Hb drops below 10g/dL, iron
deﬁciency should be excluded before starting therapy with
erythropoiesis stimulating agents. Nonetheless, patients with
HF might beneﬁt from more aggressive anemia correction in
view of the results of several cardiology trials [36–39].
5. Conclusion
Cardiorenal syndrome implies several interrelated mecha-
nisms in patients with heart failure. The appropriate strategy
to take care of these patients remains unclear, both in
acute and chronic clinical situations. In accordance with the
most plausible underlying pathophysiological mechanisms,
treatment targets should be oriented toward an adequate
intravascular volume management and to ensure a proper
renal perfusion. Although there are encouraging advances
around this unsolved clinical problem, further investigation
should consider the progressive inclusion of patients with
advanced renal impairment to allow a better understanding
of cardiorenal syndrome.
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